Investment Thesis
Akari Therapeutics is a pre-revenue biopharmaceutical company burning significant cash with critically low liquidity and a current ratio of 0.19x, indicating severe near-term solvency concerns. The company is consuming $7.5M in annual operating cash flow against only $2.5M in cash reserves, creating an unsustainable financial position without immediate capital infusion or revenue generation.
AKTX Strengths
- Zero long-term debt reduces financial leverage risk
- Minimal capital expenditure ($42.1K) suggests focus on R&D efficiency
- Stockholders equity of $22.7M provides some asset backing
AKTX Risks
- Critical liquidity crisis with current ratio of 0.19x - cannot cover current liabilities
- Only $2.5M cash against $7.5M annual operating burn rate - runway exhaustion within 4 months
- Pre-revenue stage with no demonstrated commercialization path or product revenue
- Negative ROE of -52.9% and ROA of -26.4% reflect severe capital inefficiency
- Operating losses of $14M indicate substantial ongoing cash consumption
- Minimal insider activity (1 Form 4 in 90 days) suggests limited stakeholder confidence
Key Metrics to Watch
- Monthly cash burn rate and remaining runway to profitability or next funding event
- Clinical trial progress and regulatory pathway milestones for lead candidates
- Capital raising activities and terms of any new financing arrangements
AKTX Financial Metrics
AKTX Profitability Ratios
AKTX Balance Sheet & Liquidity
AKTX 5-Year Financial Trend
5-Year Trend Summary: Akari Therapeutics Plc's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.00 indicates the company is currently unprofitable.
AKTX Growth Metrics (YoY)
AKTX Capital Allocation
AKTX SEC Filings
Access official SEC EDGAR filings for Akari Therapeutics Plc (CIK: 0001541157)